(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 December 2012 (13.12.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/171031 A1

(51) International Patent Classification:
A61K 38/36 (2006.01) *A61P 7/04* (2006.01)
A61K 38/37 (2006.01)

(21) International Application Number:
PCT/US2012/041957

(22) International Filing Date:
11 June 2012 (11.06.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/495,884	10 June 2011 (10.06.2011)	US
61/511,901	26 July 2011 (26.07.2011)	US
61/523,790	15 August 2011 (15.08.2011)	US

(71) Applicants *(for all designated States except US)*: **BAXTER INTERNATIONAL INC.** [US/US]; One Baxter Parkway, Deerfield, IL 60015 (US). **BAXTER HEALTHCARE S.A.** [CH/CH]; Thurgauerstrasse 130, CH-8152 Glattpark (Opfikon) (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SCHEIFLINGER, Friedrich** [AT/AT]; Michelbeuerngasse 4/17, A-1090 Vienna (AT). **TURECEK, Peter** [AT/AT]; Weidling, Hauptrasse 59g, A-3400 Klosterneuburg (AT). **EWENSTEIN, Bruce** [US/US]; 15 Claflin Path, Brookline, MA 02445-4401 (US). **WONG, Wing, Yen** [US/US]; 544 Winncastle Street, Simi Valley, CA 93065 (US). **SUITER, Tobias, M.** [AT/AT]; Kleine Sperlgasse 1-36, A-1020 Vienna (AT).

(74) Agent: **TALUKDER, Gargi**; Morgan, Lewis & Bockius LLP, One Market, Spear Street Tower, San Francisco, CA 94105 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: TREATMENT OF COAGULATION DISEASE BY ADMINISTRATION OF RECOMBINANT VWF

FIG. 3



	r	pd
$T_{½}$ [hours]	24.3 (6.5)	19 (5.1)
IR [(U/dL)/(U VWF:RCo/kg)]	2.1 (0.8)	1.3 (0.3)
MRT [hours]	38.9 (12.4)	32.7 (7.5)
$AUC_{0-\infty}$ [h*U/dL]	5376 (2380)	3361 (1350)
r = rVWF/rFVIII pd = pdVWF/pdFVIII		

(57) Abstract: The present invention provides methods of treating coagulation disease, including hemophilia and von Willebrand disease by administering recombinant von Willebrand Factor alone or in combination with Factor VIII.

WO 2012/171031 A1

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*